The National Institutue for Health and Clinical Excellence (NICE) has issued its Final Appraisal Determination (FAD) on sunitinib for the treatment of gastrointestinal stromal tumours. 

Sunitinib is recommended as a treatment option for people with unresectable and/or metastatic malignant gastrointestinal stromal tumours if:

• imatinib treatment has failed because of resistance or
  intolerance, and
• they have an Eastern Cooperative Oncology Group (ECOG)
  performance status of 0 or 1 (i.e. good performance status).

NOTE: An ECOG performance status of 0 means the person is fully active, able to carry on all pre-illness performance without restriction. A performance status of 1 means the person is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light house work, office work.